Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
Marsavela G, Lee J, Calapre L, Wong SQ, Pereira MR, McEvoy AC, Reid AL, Robinson C, Warburton L, Abed A, Khattak MA, Meniawy TM, Dawson SJ, Sandhu S, Carlino MS, Menzies AM, Scolyer RA, Long GV, Amanuel B, Millward M, Ziman MR, Rizos H, Gray ES.
Marsavela G, et al. Among authors: reid al.
Clin Cancer Res. 2020 Nov 15;26(22):5926-5933. doi: 10.1158/1078-0432.CCR-20-2251. Epub 2020 Oct 16.
Clin Cancer Res. 2020.
PMID: 33067256